FEDERAL STATE INSTITUTION SAINT PETERSBURG RESEARCH INSTITUTE OF PHTHISIOPULMONOLOGY OF THE FEDERAL AGENCY FOR HIGH TECHNOLOGY MEDICAL AID

Their core work

SPB RIPP is a federal clinical research institute in Saint Petersburg specializing in phthisiopulmonology — the diagnosis, treatment, and epidemiology of tuberculosis and other pulmonary infections. Their core work encompasses both clinical patient care and applied research on drug-resistant TB, placing them at the intersection of frontline treatment and translational science. In international consortia, they contribute clinical expertise, access to Russian patient cohorts, and deep knowledge of multidrug-resistant tuberculosis — a disease burden where Russia carries disproportionate global weight. Their H2020 participation spans clinical-network collaboration on HIV/TB/HCV co-infections and theoretical investigation of the molecular mechanisms driving antimicrobial resistance in TB.

What they specialise in

How they've shifted over time

Both H2020 projects launched in the same year (2019), so a longitudinal shift within their EU portfolio cannot be measured in the conventional sense. What the data does reveal is a meaningful thematic split: CARE represents clinical-network engagement focused on reducing HIV/TB/HCV burden across regions, while AMR-TB reflects a more computational, mechanistic orientation — moving from bedside epidemiology toward molecular modelling of resistance. If this pairing signals a strategic direction, SPB RIPP appears to be broadening from pure clinical research into computational biology applied to infectious disease, using TB as the model organism.

SPB RIPP is extending its clinical TB expertise into computational resistance modelling, suggesting future collaborations in AMR prediction, drug design validation, or pathogen evolution simulation would be well-matched.

How they like to work

SPB RIPP has never coordinated an H2020 project, always entering consortia as a participant or third party — a pattern consistent with a specialist clinical institution that contributes domain expertise rather than managing project logistics. Their two projects together involved 29 unique partners across 13 countries, suggesting they are comfortable operating within large, geographically distributed consortia. This makes them a reliable specialist node rather than a project driver, valuable to consortium builders who need credible clinical or epidemiological capacity in the Russian/Eastern European TB context.

SPB RIPP has reached 29 unique consortium partners across 13 countries through just two projects, indicating that both consortia were large and geographically broad. Their network spans Europe and likely includes Eastern European and Central Asian partners given the TB epidemiology focus.

What sets them apart

SPB RIPP is one of Russia's leading federal TB research institutions, giving it access to patient cohorts, clinical data, and resistance surveillance from a country with one of the world's highest burdens of multidrug-resistant TB — a resource few European partners can replicate. Their dual footing in clinical medicine and computational resistance modelling positions them as a bridge between laboratory science and real-world TB epidemiology. For consortia addressing AMR, infectious disease policy, or global health equity, access to the Russian TB clinical environment is a distinct and hard-to-substitute asset.

Highlights from their portfolio

• AMR-TB
  A long-running RIA project (2019–2025) applying theoretical and computational methods — molecular dynamics, fitness landscapes, metabolic pathway analysis — to explain how TB develops antimicrobial resistance, representing SPB RIPP's most technically specialized EU engagement.
• CARE
  A pan-European MSCA-RISE action tackling the HIV/TB/HCV co-epidemic across regions, bringing SPB RIPP into a clinical network that spans Eastern and Western Europe under a shared public health mandate.